General Information and Variability Data of DT
DT ID	DTD0031
Gene Name	SLCO2B1
Protein Name	Organic anion transporting polypeptide 2B1
Synonyms	KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; SLC21A9; SLCO2B1; Solute carrier family 21 member 9; Solute carrier organic anion transporter family member 2B1
Gene ID	11309
UniProt ID	O94956
TCDB ID	2.A.60.1.20
DT Family	Organo Anion Transporter (OAT) Family ;
Tissue Specificity	Isoform 1 has it's highest expression inbrain, it is the major form expressed in duodenum, kidney,placenta, and skeletal muscle. Isoform 3 predominates in liver.
Function	This Na(+)-independent transporter mediates the transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Disease(s)	Diabetes [ICD-11: 5A10-5A14]
	Dry eye disease [ICD-11: 9A79]
	Dyslipidaemias [ICD-11: 5C8Z]
	High blood pressure [ICD-11: BA00]
	Human immunodeficiency virus infection [ICD-11: 1C62.Z]
	Medical abortion [ICD-11: JA00.1]
	Open angle glaucoma [ICD-11: 9C61]
	Pulmonary arterial hypertension [ICD-11: BB01.0]
	Renal cell carcinoma [ICD-11: 2C90]
Genetic Polymorphisms & Epigenetic Regulations of DT	Epigenetic Regulations of DT (ERD)
	Genetic Polymorphisms of DT (GPD)
Species-, Tissue- and Disease-specific Protein Abundances of DT	Disease-specific Protein Abundances of DT (DPAD)
	Species/Tissue-specific Protein Abundances of DT (S/TPAD)
Exogenous Factor Altering DT Activity	Exogenous Factors (drugs, dietary constituents, natural products, etc.) Modulating DT Activity (EFMDA)
Approved Drug(s) Transported by This DT	Abiraterone acetate	Drug Info	Prostate cancer [ICD-11: 2C82]	Approved	[1]
	Aliskiren fumarate	Drug Info	High blood pressure [ICD-11: BA00]	Approved	[2]
	Atorvastatin	Drug Info	Hyperlipidaemia [ICD-11: 5C8Z]	Approved	[3]
	Bosentan	Drug Info	Pulmonary arterial hypertension [ICD-11: BB01.0]	Approved	[4]
	Cerivastatin	Drug Info	Hyperlipidaemia [ICD-11: 5C8Z]	Approved	[5]
	Dehydroepiandrosterone sulfate	Drug Info	Dyspareunia [ICD-11: GA12]	Approved	[6]
	Digoxin	Drug Info	Arrhythmias [ICD-11: BC60-BC9Z]	Approved	[7]
	Dinoprostone	Drug Info	Medical abortion [ICD-11: JA00.1]	Approved	[8]
	Eltrombopag	Drug Info	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10]	Approved	[9]
	Estrone sulfate	Drug Info	Menopausal symptoms [ICD-11: MF32]	Approved	[10]
	Etoposide	Drug Info	Testicular cancer [ICD-11: 2C80]	Approved	[11]
	Fexofenadine	Drug Info	Allergic rhinitis [ICD-11: CA08.0]	Approved	[12]
	Fluvastatin	Drug Info	Hypercholesterolemia [ICD-11: 5C80.0]	Approved	[10]
	Glibenclamide	Drug Info	Diabetes [ICD-11: 5A10-5A14]	Approved	[13]
	L-glutamic acid	Drug Info	Schizophrenia [ICD-11: 6A20]	Approved	[14]
	Latanoprost	Drug Info	Open angle glaucoma [ICD-11: 9C61]	Approved	[15]
	Latanoprostene bunod	Drug Info	Renal cell carcinoma [ICD-11: 2C90]	Approved	[15]
	Lifitegrast	Drug Info	Dry eye disease [ICD-11: 9A79]	Approved	[16]
	Mesalazine	Drug Info	Recurrent ventricular fibrillation [ICD-11: BC71.1]	Approved	[17]
	Montelukast	Drug Info	Asthma [ICD-11: CA23]	Approved	[18]
	Pemetrexed	Drug Info	Malignant pleural mesothelioma [ICD-11: 2C26.0]	Approved	[19]
	Pitavastatin	Drug Info	Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z]	Approved	[20]
	Pitavastatin calcium	Drug Info	Dyslipidaemias [ICD-11: 5C8Z]	Approved	[21]
	Pravastatin	Drug Info	Hypercholesterolemia [ICD-11: 5C80.0]	Approved	[22]
	Ritonavir	Drug Info	Human immunodeficiency virus infection [ICD-11: 1C62.Z]	Approved	[23]
	Rocuronium	Drug Info	Muscle relaxant [ICD-11: XM31L2]	Approved	[7]
	Rosuvastatin	Drug Info	Hypercholesterolemia [ICD-11: 5C80.0]	Approved	[24]
	Sulfasalazine	Drug Info	Rheumatoid arthritis [ICD-11: FA20]	Approved	[25]
	Telmisartan	Drug Info	High blood pressure [ICD-11: BA00]	Approved	[26]
Clinical Trial Drug(s) Transported by This DT	Benzylpenicillin	Drug Info	Gram-positive bacteria infections [ICD-11: 1A00-1H0Z]	Phase 4	[8]
	M17055	Drug Info	Diuretic vasodilator [ICD-11: BA00]	Phase 3	[27]
	Talinolol	Drug Info	Gastrointestinal motility disorder [ICD-11: DE2Z]	Phase 1	[28]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT	Scutellarin	Drug Info	Cerebrovascular ischaemia [ICD-11: 8B1Z]	Preclinical	[29]
	Sodium taurocholate	Drug Info	Type 2 diabetes [ICD-11: 5A11]	Preclinical	[22]
	Taurocholic acid	Drug Info	Type 2 diabetes [ICD-11: 5A11]	Terminated	[22]
Endogenous Substrate(s)	Organoanions
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data	Atorvastatin	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 2.84 microM	[30]
	Atorvastatin	Drug Info	Madin-Darby canine kidney cells (MDCKII)-OATP2B1	Km = 0.2 microM	[31]
	Bosentan	Drug Info	Chinese hamster ovary (CHO) cells-OATP2B1	Km = 202 microM	[4]
	Bromsulphthalein	Drug Info	Oocytes-OATP2B1	Km = 0.7 microM	[32]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 1.56 microM	[33]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 7.14 microM	[13]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 8.09 microM	[22]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 10.2 microM	[10]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 12.5 microM	[34]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 13.1 microM	[22]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 20.9 microM	[21]
	Estrone sulfate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 38.24 microM	[30]
	Estrone sulfate	Drug Info	Human enterocyte-like 2 cells (Caco-2)-OATP2B1	Km = 1.81 microM	[33]
	Estrone sulfate	Drug Info	Oocytes-OATP2B1	Km = 6.3 microM	[32]
	Fluvastatin	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 0.75 microM	[10]
	Glibenclamide	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 6.26 microM	[13]
	Mesalazine	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 188.9 microM	[17]
	Pitavastatin calcium	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 1.17 microM	[21]
	Pravastatin	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 2250 microM	[22]
	Rosuvastatin	Drug Info	Human cervical cancer cell line (Hela)-OATP2B1	Km = 2.4 microM	[35]
	Rosuvastatin	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 6.42 microM	[24]
	Sodium taurocholate	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 71.8 microM	[22]
	Taurocholic acid	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 71.8 microM	[22]
	Telmisartan	Drug Info	Human embryonic kidney cells (HEK293)-OATP2B1	Km = 1.09 microM	[26]
References
1	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311.
2	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26.
3	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
4	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
5	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
6	Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372.
7	Drug Interactions in Infectious Diseases.
8	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
9	Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
10	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
11	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
12	The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
13	Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
14	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
15	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
16	Clinical Pharmacology and Biopharmaceutics review(s)
17	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
18	Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
19	Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
20	Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9.
21	Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
22	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
23	pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
24	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
25	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
26	Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
27	Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8.
28	Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9.
29	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
30	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
31	Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20.
32	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
33	Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006 Aug;34(8):1423-31.
34	Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9.
35	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.